Europe’s Premier Meeting Shaping the Future of Obesity & Weight Loss Development
The future of obesity treatment will be defined by those who move beyond weight loss alone. Explore the breakthroughs redefining obesity drug development, from novel targets and combination approaches to emerging modalities to deliver superior healthy weight-management outcomes that set the next industry benchmark in this crowded space.
Expect unmissable insight-rich conversations that go beyond the data with the industry’s leading c-suite executives, decision makers and leading solution providers, to advance your therapy through the clinic.
Unmissable Event Highlights
Unlock Next-Gen Targets
Explore new targets including GIP, B2 receptors and amylin to discover opportunities to leverage the body’s metabolic pathways rather than override them for safe, prolonged efficacy with Antag Therapeutics, Boehringer Ingelheim, Atrogi, Aphaia Pharma and more
Optimize Clinical Trials
Combat key side effects to increase patient adherence and stronger long-term outcomes with Cantoni Therapeutics, Novo Nordisk, and iBio
Master Combination Therapies
Determine which modality will define obesity treatment's next era by balancing efficacy, durability, and patient-friendly delivery to achieve lasting clinical impact with Alveus Therapeutics, ScionXBio, and Atrogi Therapeutics.
Leverage the latest understanding of obesity pathology to identify new intervention points and broaden treatment potential
Attending Companies Included